Pro zobrazení tohoto obsahu je třeba být přihlášen.
Author Archives for m.popovic@wemakemedia.cz
ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) WHO REQUIRE TWO COURSES OF INDUCTION THERAPY TO ACHIEVE COMPLETE REMISSION (CR) SHOULD UNDERGO ALLOGENEIC TRANSPLANT (ALLO-SCT) DURING THE FIRST CR
15 októbra, 2020 7:26 pm Leave your thoughtsAuthor(s): Hiroaki Shimizu, Hiroshi Handa, Nahoko Hatsumi, et. al. Abstract: ABSSUB-4989 Session topic: 4. Acute myeloid leukemia –...
RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AZACITIDINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
15 októbra, 2020 7:26 pm Leave your thoughtsAuthor(s): Hervé Dombret, John F. Seymour, Aleksandra Butrym, et. al. Abstract: LB-6212 Session topic: 4. Acute myeloid leukemia...
VALIDATION OF EUROPEAN LEUKEMIA NET (ELN) GUIDELINES FOR CYTOGENETICALLY NORMAL AML IN ASSOCIATION WITH NPM1 AND FLT3-ITD MUTATIONS: FURTHER STRATIFICATION FOCUSING ON WT1 EXPRESSION
15 októbra, 2020 7:26 pm Leave your thoughtsAuthor(s): Jae-Ho Yoon, Hee-Je Kim, Young-Woo Jeon, et. al. Abstract: ABSSUB-3999 Session topic: 4. Acute myeloid leukemia –...
Akútna myeloblastová leukémia
15 októbra, 2020 7:26 pm Leave your thoughtsKongres potvrdil významný pokrok v poznatkoch o patogenéze akútnej myeloblastovej leukémie (AML), v rozvoji diagnostických vyšetrení a nových terapií. Rozlúštil sa molekulovogenetický a epigenetický základ...
5-YR RESULTS FROM THE PIVOTAL PHASE 2 PONATINIB PACE TRIAL: EFFICACY, SAFETY AND LANDMARK ANALYSIS IN HEAVILY PRETREATED PATIENTS (PTS) WITH CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
15 októbra, 2020 7:26 pm Leave your thoughtsAuthor(s): Jorge E Cortes, Hagop M Kantarjian, Javier Pinilla-Ibarz, et. al. Abstract: P 603 Session topic: 8. Chronic...
ASSESSMENT OF IMATINIB 400MG AS FIRST LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: 10 -YEAR SURVIVAL RESULTS OF THE RANDOMIZED CML STUDY IV
15 októbra, 2020 7:26 pm Leave your thoughtsAuthor(s): Ruediger Hehlmann, Michael Lauseker, Susanne Saussele et. al. Abstract: S 424 Session topic: 8. Chronic myeloid leukemia...
DURABLE TREATMENT-FREE REMISSION (TFR) AFTER STOPPING SECOND-LINE NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTOP 96-WK UPDATE
15 októbra, 2020 7:26 pm Leave your thoughtsAuthor(s): Timothy Hughes, Carla Boquimpani, Naoto Takahashi, et al Abstract: P 257 Session topic: 8. Chronic myeloid leukemia...
IMPACT OF ARTERIAL THROMBOTIC EVENTS ON THE LONG-TERM OUTCOME OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS TREATED IN FIRST-LINE WITH NILOTINIB: AN ANALYSIS OF THE GIMEMA CML WORKING PARTY
15 októbra, 2020 7:26 pm Leave your thoughtsAuthor(s): Gabriele Gugliotta, Fausto Castagnetti, Massimo Breccia, et. al. Abstract: P 605 Session topic: 8. Chronic myeloid leukemia...
Aktuality z EHA 2017 zaměřené na chronickou myeloidní leukemii
15 októbra, 2020 7:26 pm Leave your thoughtsChronická myeloidní leukemie (CML) je klonální myeloproliferativní onemocnění, které představuje 15–25 % nově diagnostikovaných leukemií dospělého věku. Je příkladem onemocnění, u kterého...
COMBINATION THERAPY OF POMALIDOMIDE PLUS RUXOLITINIB IN MYELOFIBROSIS: RESULTS FROM COHORT 1 OF THE MPNSG-0212 TRIAL (NCT01644110)
15 októbra, 2020 7:26 pm Leave your thoughtsAuthor(s): Frank Stegelmann, Martin Griesshammer, Steffen Koschmieder Abstract: P 700 Session topic: 16. Myeloproliferative neoplasms – Clinical ...